Table 3.

LncRNA Expression Profile in Patients with NAFLD with Different Fibrosis Stages. “⤤”, “⤦”, “⟷” indicates the expression direction.

Fibrosis	lncRNA	Species	Sample Size	Expression	Fold-Change	p Value	Study
F0 vs. F1–4	MALAT1	liver	13 HC/47 NAFLD	⤤	5	1 × 10−7	Sookoian, 2018 [41]
	MEG3	liver	6 HC/6 fibrosis	⤤	2.2	<0.01	Zhang, 2017 [39]
	MEG3	liver	10HC/15 fibrosis	⤦	0.3	<0.01	Zou, 2022 [40]
F0–2 vs. F3	GAS5	liver	39 F0-2/6 F3	⟷	-	0.131	Han, 2020 [49]
	GAS5	plasma	39 F0-2/6 F3	⤤	2.02	<0.001	Han, 2020 [49]
F0–2 vs. F3–4	TGFB2/TGFB2-OT1	serum	37 F0-2/26 F3-4	⤤	1.82	≤0.001	Di Mauro, 2019 [43]
	RP11-128N14.5	serum	37 F0-2/26 F3-4	⟷	-	>0.05	Di Mauro, 2019 [43]
F0–1 vs. F4	lnc-SPARCL1-1:2	serum	25 F0-1/10 F4	⤤	-	<0.05	Albadawy, 2021 [23]
	lncRNA RABGAP1LDT-206	serum	34 F3/11 F4	⤤	-	<0.05	Albadawy, 2021 [34]
F2 vs. F4	lnc-SPARCL1-1:2	serum	20 F2/10 F4	⤤	-	<0.05	Albadawy, 2021 [23]
	lncRNA RABGAP1LDT-206	serum	26 F2/11 F4	⤤	-	<0.05	Albadawy, 2021 [34]
F3 vs. F4	GAS5	liver	6 F3/6 F4	⟷	-	0.818	Han, 2020 [49]
	GAS5	plasma	6 F3/6 F4	⤦	0.54	0.026	Han, 2020 [49]
	lnc-SPARCL1-1:2	serum	24 F3/10 F4	⤤	-	<0.05	Albadawy, 2021 [23]
	lncRNA RABGAP1LDT-206	serum	29 F3/11 F4	⤤	-	<0.05	Albadawy, 2021 [34]
(advanced fibrosis) vs. (not advanced fibrosis)	LeXis	serum	33/11	⟷	-	0.328	Park, 2020 [45]
		liver	33/11	⟷	-	0.14	Park, 2020 [45]
	NEAT1	liver	24/53	⤤	1.29	3 × 10−4	Leti, 2017 [47]
	HULC	liver	24/53	⤤	3.6	1.08 × 10−8	Leti, 2017 [47]
	MALAT1	liver	24/53	⤤	3.6	8.02 × 10−6	Leti, 2017 [47]
	LINC01638	liver	10/10	⤤	2.81	≤0.001	Gerhard, 2020 [51]
	LINC01605	liver	10/10	⟷	-	>0.05	Gerhard, 2020 [51]
	XLOC_003146	liver	10/10	⤤	1.65	≤0.0001	Gerhard, 2020 [51]
	RP11_20J153	liver	10/10	⤤	1.34	≤0.0001	Gerhard, 2020 [51]
HC vs. cirrhosis	GAS5	liver	15/20	⤦	0.43	<0.01	Yu, 2015 [50]
	MEG3	liver	6/8	⤤	2.2	<0.01	Zhang, 2017 [39]
	H19	liver	6/17	⤤	3.67	<0.05	Liu, 2018 [52]